FDA's Overreach on Compounded Peptides BPC 157 FDA Approval Status 2026: RFK Jr, Advisory Committee & Reclassification The FDA just put BPC 157 on the calendar. July 2324 advisory panel votes on whether to restore legal compounding access for BPC 157, TB 500, and 5 more restricted peptides. This is the FDA July 2026 Peptide Meeting: What Patients Need to Know About Access, Approval, and Safety Meto blog FDA Moves to Reevaluate Several Peptides American Med Spa Association Should You Try MOTS c and BPC 157 Longevity Peptides? Separating Truth from Hype with Human Data Studies